BACKGROUND: Stereotactic radiotherapy (SRT) is fractionated radiotherapy delivered under stereotactic guidance to produce highly focal and precise therapy. We studied the incidence of imaging changes that can mimic tumor progression after completion of SRT for childhood low grade astrocytoma. METHODS: Between June 1992 and September 1994, we prospectively treated 28 children with low grade astrocytomas with SRT. The patients ranged in age from 2 to 22 years (median: 10 yrs) and none had received prior radiation therapy or radiosurgery. Routine fractionation was employed (180-200 centigray[cGy]) to a total dose of 5220-6000 cGy over 5 to 6 weeks. All of the patients underwent initial and follow-up magnetic resonance imaging (MRI) according to protocol. RESULTS: Median clinical follow-up for the 28 patients was 24 months (range, 5-32 mos) with a median radiographic follow-up of 15 months (range, 3-26 mos). Fifteen patients had reduction in tumor size, one patient had stable disease. Twelve patients (43%) developed increased size of the lesion, increased signal intensity or enhancement, cysts or cavitations, and an increase in edema or mass effect on follow-up MRI. Most of these changes occurred between 9 and 12 months after the start of SRT and resolved or decreased by 15 to 21 months. All but one patient had normal or stable neurologic examinations. CONCLUSIONS: Treatment-related MRI changes are common after conventionally fractionated schedules using stereotactic radiation techniques for patients with low grade astrocytomas. These changes can be distinguished from tumor progression by their transient nature as well as the general absence of clinical symptoms.
BACKGROUND: Stereotactic radiotherapy (SRT) is fractionated radiotherapy delivered under stereotactic guidance to produce highly focal and precise therapy. We studied the incidence of imaging changes that can mimic tumor progression after completion of SRT for childhood low grade astrocytoma. METHODS: Between June 1992 and September 1994, we prospectively treated 28 children with low grade astrocytomas with SRT. The patients ranged in age from 2 to 22 years (median: 10 yrs) and none had received prior radiation therapy or radiosurgery. Routine fractionation was employed (180-200 centigray[cGy]) to a total dose of 5220-6000 cGy over 5 to 6 weeks. All of the patients underwent initial and follow-up magnetic resonance imaging (MRI) according to protocol. RESULTS: Median clinical follow-up for the 28 patients was 24 months (range, 5-32 mos) with a median radiographic follow-up of 15 months (range, 3-26 mos). Fifteen patients had reduction in tumor size, one patient had stable disease. Twelve patients (43%) developed increased size of the lesion, increased signal intensity or enhancement, cysts or cavitations, and an increase in edema or mass effect on follow-up MRI. Most of these changes occurred between 9 and 12 months after the start of SRT and resolved or decreased by 15 to 21 months. All but one patient had normal or stable neurologic examinations. CONCLUSIONS: Treatment-related MRI changes are common after conventionally fractionated schedules using stereotactic radiation techniques for patients with low grade astrocytomas. These changes can be distinguished from tumor progression by their transient nature as well as the general absence of clinical symptoms.
Authors: Joel M Cherlow; Dennis W W Shaw; Linda R Margraf; Daniel C Bowers; Jie Huang; Maryam Fouladi; Arzu Onar-Thomas; Tianni Zhou; Ian F Pollack; Amar Gajjar; Sandy K Kessel; Patricia L Cullen; Kevin McMullen; John C Wellons; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-10 Impact factor: 7.038
Authors: Sheema Chawla; David N Korones; Michael T Milano; Ali Hussain; Abdel R Hussien; Ann G Muhs; Manisha Mangla; Howard Silberstein; Sven Ekholm; Louis S Constine Journal: J Neurooncol Date: 2012-01-12 Impact factor: 4.130
Authors: V Strenger; H Lackner; R Mayer; P Sminia; P Sovinz; M Mokry; A Pilhatsch; M Benesch; W Schwinger; M Seidel; D Sperl; S Schmidt; C Urban Journal: Strahlenther Onkol Date: 2013-08-22 Impact factor: 3.621
Authors: B Amini; C B Beaman; J E Madewell; P K Allen; L D Rhines; C E Tatsui; N M Tannir; J Li; P D Brown; A J Ghia Journal: AJNR Am J Neuroradiol Date: 2015-10-22 Impact factor: 3.825
Authors: Derek S Tsang; Erin S Murphy; John T Lucas; Pagona Lagiou; Sahaja Acharya; Thomas E Merchant Journal: J Neurooncol Date: 2017-07-27 Impact factor: 4.130
Authors: Jodi A Muscal; Jeremy Y Jones; Arnold C Paulino; Alison A Bertuch; Jack Su; Shiao Y Woo; Donald H Mahoney; Murali Chintagumpala Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-15 Impact factor: 7.038